BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27943415)

  • 1. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
    Algrin C; Golmard JL; Michallet M; Reman O; Huynh A; Perrot A; Sirvent A; Plesa A; Salaun V; Béné MC; Bories D; Tournilhac O; Merle-Béral H; Leblond V; Le Garff-Tavernier M; Dhedin N
    Eur J Haematol; 2017 Apr; 98(4):363-370. PubMed ID: 27943415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
    Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
    Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
    Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
    Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
    Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
    Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status.
    Esteve J; Villamor N; Colomer D; Cervantes F; Campo E; Carreras E; Montserrat E
    Leukemia; 2001 Mar; 15(3):445-51. PubMed ID: 11237069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
    Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.
    Chakupurakal G; Leitzke S; Langerbeins P; Schiller J; Schneider PM; Holtick U; Shimabukuro-Vornhagen A; Theurich S; Chemnitz J; Hallek M; von Bergwelt-Baildon M; Scheid C
    Ann Hematol; 2015 Oct; 94(10):1717-25. PubMed ID: 26259502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.
    Ritgen M; Böttcher S; Stilgenbauer S; Bunjes D; Schubert J; Cohen S; Humpe A; Hallek M; Kneba M; Schmitz N; Döhner H; Dreger P;
    Leukemia; 2008 Jul; 22(7):1377-86. PubMed ID: 18418404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
    Thompson PA; Wierda WG
    Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.
    Rossi G; Carella AM; Minervini MM; di Nardo F; Waure Cd; Greco MM; Merla E; Cillis GP; Di Renzo N; Melpignano A; Capalbo S; Palumbo G; Pisapia G; Cascavilla N
    Leuk Res; 2015 Feb; 39(2):138-43. PubMed ID: 25498507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia.
    Klyuchnikov E; Badbaran A; Massoud R; Fritsche-Friedland U; Janson D; Ayuk F; Christopeit M; Wolschke C; Bacher U; Kröger N
    Transplant Cell Ther; 2022 May; 28(5):267.e1-267.e7. PubMed ID: 35066212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of Monitoring Minimal Residual Disease by Flow Cytometry in Acute Leukemia Patients Underwent Nonmyeloablative Allo-HSCT].
    Liu XX; Liu TQ; Guo M; Sun QY; Qiao JH; Hu KX; Li BX; Yao B; Yu CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):873-879. PubMed ID: 28641652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL.
    Sanchez-Garcia J; Serrano J; Serrano-Lopez J; Gomez-Garcia P; Martinez F; Garcia-Castellano JM; Rojas R; Martin C; Rodriguez-Villa A; Molina-Hurtado JR; Alvarez MA; Casaño J; Torres-Gomez A
    Bone Marrow Transplant; 2013 Mar; 48(3):396-402. PubMed ID: 22858507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
    Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
    Gauthier M; Comont T; Vergez F; Ysebaert L
    Bull Cancer; 2018 Nov; 105(11):1042-1051. PubMed ID: 30243477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.